Revised criteria for the diagnosis of mild cognitive impairment (MCI) could compromise the diagnosis of Alzheimer disease (AD) dementia, according to an analysis published online Feb. 6 in Archives of Neurology.
Family history of Alzheimer disease (AD) is associated with several age-related changes that appear to influence AD biomarker abnormalities beyond the increased risk of the APOE4 gene, according to a report published in the October issue of Archives of Neurology. Previously, researchers suspected that AD has a lengthy preclinical period prior to the development of symptoms, in which cerebral lesions accumulate.
Written by Jim Brice
One of the variables with the effects of cancer is hypoxia, and a PET-based imaging technique may be capable of measuring and mapping it. Researchers at Washington University in St. Louis are focusing on two aspects of the investigational PET probe Cu-62 ATSM for hypoxia imaging.
Written by James Brice
Slowly but steadily, radiation oncologists are adopting PET and PET/CT to measure the early response of cancers to radiotherapy and other treatments. And progress has been significant.
A combination of well-known safety procedures could prevent most patient-harming errors in radiation therapy, according to a study presented at the annual meeting of the American Association of Physicists in Medicine (AAPM) and Canadian Organization of Medical Physicists, July 31 to Aug. 4 in Vancouver, Canada.
Individuals with deterministic genes in whom it is known that Alzheimer’s disease (AD) will develop appear to show differences in beta-amyloid distribution when compared with non-dominantly inherited AD patients, helping to consolidate evidence that PET and MRI can depict brain changes well before the arrival of AD-related symptoms, according to preliminary findings presented July 20 at the 2011 Alzheimer’s Association International Conference in Paris.
Sunday, June 5 | 4:15 AM - 5:45 PM
Room 006CD
Written by C.P. Kaiser
While PET/CT is commonly and very successfully used for the staging and follow-up of cancers, researchers are seeking ways to make the modality more sensitive and specific by using targeted radiotracers and refining scanning techniques.
Written by Manjula Puthenedam, PhD
PET imaging is effective in staging, restaging, detecting recurrence and treatment monitoring across a wide range of cancers. This feature discusses updates on important PET imaging clinical trials in cancer care by the American College of Radiology Imaging Network and National Cancer Institute and focuses on improving cancer staging and predicting response to therapy. The National Oncology PET Registry (NOPR) recently published the results of the impact of dedicated brain PET on intended patient management and opened a registry for 18F-sodium fluoride PET to identify bone metastasis. The Cancer and Leukemia Group B (CALGB) sponsored by the NCI is another group conducting clinical trials in cancer, yet PET trials are still few.
